Radium Historical Items Catalog
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Cutaneous Manifestations of COVID-19: a Systematic Review and Analysis of Individual Patient-Level Data
Volume 26 Number 12| December 2020 Dermatology Online Journal || Review 26(12):2 Cutaneous manifestations of COVID-19: a systematic review and analysis of individual patient-level data David S Lee1 MD, Paradi Mirmirani2,3 MD, Patrick E McCleskey4 MD, Majid Mehrpouya5 PhD, Farzam Gorouhi6,7 MD Affiliations: 1Department of Dermatology, The Permanente Medical Group, Pleasanton, California, USA, 2Department of Dermatology, University of California, San Francisco, California, USA, 3Department of Dermatology, The Permanente Medical Group, Vallejo, California, USA, 4Department of Dermatology, The Permanente Medical Group, Oakland, California, USA, 5Faculty of Engineering, University of Calgary, Calgary, Alberta, Canada, 6Department of Dermatology, The Permanente Medical Group, South Sacramento, California, USA, 7Department of Dermatology, University of California, Davis, California, USA Corresponding Author: Farzam Gorouhi MD FAAD, Kaiser Permanente, South Sacramento, 6600 Bruceville Road, Sacramento, CA 95823, Tel: 415-298-1345, Email: [email protected] Introduction Abstract In December 2019, reports from Wuhan, China Distinctive patterns in the cutaneous manifestations described new clusters of patients with severe of COVID-19 have been recently reported. We pneumonia linked to a novel coronavirus strain, now conducted a systematic review to identify case reports and case series characterizing cutaneous referred to as severe acute respiratory syndrome manifestations of confirmed COVID-19. Key coronavirus 2 (SARS-CoV-2), [1]. Coronavirus disease demographic and clinical data from each case were 2019 (COVID-19) has since reached pandemic extracted and analyzed. The primary outcome proportions, with over 12·7 million cases worldwide, measure was risk factor analysis of skin related 566,000 deaths, and 188 countries affected at the outcomes for severe COVID-19 disease. -
Prevalence, Sources and Purpose of Self-Prescribed Non-Opioid
DOI: 10.1515/cipms-2018-0003 Curr. Issues Pharm. Med. Sci., Vol. 31, No. 1, Pages 13-17 Current Issues in Pharmacy and Medical Sciences Formerly ANNALES UNIVERSITATIS MARIAE CURIE-SKLODOWSKA, SECTIO DDD, PHARMACIA journal homepage: http://www.curipms.umlub.pl/ Prevalence, sources and purpose of self-prescribed non-opioid analgesic among health professionals in Sokoto metropolis, Nigeria: a cause for concern Catherine Fidelis1,2, Kehinde Kazeem Kanmodi2,3, Johnson Olajolumo4 1 Department of Pharmacy, Usmanu Danfodiyo University Teaching Hospital, Sokoto, Nigeria 2 Cephas Health Research Initiative Inc, Ibadan, Nigeria 3 Community Health Officers Training Programme, Usmanu Danfodiyo University Teaching Hospital, Sokoto, Nigeria 4 Department of Internal Medicine, Obafemi Awolowo University Teaching Hospital, Ile-Ife, Nigeria ARTICLE INFO ABSTRACT Received 18 November 2017 Background. Self-medication is defined as the use of medicines without a doctor’s Accepted 23 December 2017 prescription. The non-opioid analgesics (NOAs) constitute one of the most commonly Keywords: self-prescribed drugs globally. This study aims to determine the prevalence of NOAs analgesics, self-medication, and also explore the purpose and sources of the self-prescribed NOAs self-prescription, among health professionals in Sokoto metropolis, Nigeria. health professionals, Nigeria. Methods. Data obtained from a cross-section of 205 health professionals in Sokoto metropolis, Nigeria, were used for this study. The study tool used was a well-structured questionnaire. Data analysis was done using the SPSS version 20 software. Results. Only 36.6% of the 205 subjects were within the age range of 26 to 30 years, 38.0% were nurses. The majority (85.9%) of the subjects had self-prescribed NOAs, of which 6.8% of them had a positive history treatment for NOA overdose. -
Camphor Revisited: Focus on Toxicity
Camphor Revisited: Focus on Toxicity Committee on Drugs This commentary updates a previous AAP state- TABLE. List of Camphor-Containing Products ment developed by the Committee on Drugs con- Product % of Camphor cerning camphor.1 The original commentary re- Absorbine Arthritic Pain Lotion 10 flected the level of concern among pediatric Act-On Rub Lotion 1.5 practitioners and poison centers about the toxicity of Anabaim Lotion 3 camphor. Since the original statement, the Food and Aveeno Anti-Itch Conc. Lotion 0.3 t Drug Administration (FDA) has recognized camphor Avalgesic Banaig Muscle Pain Reliever 2 as a safe and effective topical antitussive, analgesic, Bangesic t anesthetic, and antipruritic agent.2 Following the ap- Ben Gay Children’s Vaporizing Rub 5 proval process in 1983, the FDA required that the Betuline Lotion t concentration of camphor in products not exceed Campho-phemque First Aid Gel 10.8 Campho-phenique Uquid 10.85 11%.2 Fligher concentrations were not more effective Campho-phemque Powder 4.375 and could cause more serious adverse reactions if Counterpain Rub t accidentally ingested. Most reported camphor-re- Deep Down Rub 0.5 lated fatalities involved agents containing a concen- Dencorub Cream Dermal Rub t tration greater than 11%. Dermolin Liniment t Ingestion of potentially toxic substances by chil- Emul-O-Balm 1.1 dren is related to the availabffity of a product in their Heet Lotion 3 3.6 environment. Camphor remains widely available Heat Spray Minit-Rub 3.5 (Table). The toxicity of camphor when inappropri- Mollifene Ear Drops t ately used is well documented.6 Ingestion is the Musterole Regular 4 most common route of potentially toxic exposure, Panalgesic 3 with rapid onset of toxic effects. -
Dermatologic Manifestations and Complications of COVID-19
American Journal of Emergency Medicine 38 (2020) 1715–1721 Contents lists available at ScienceDirect American Journal of Emergency Medicine journal homepage: www.elsevier.com/locate/ajem Dermatologic manifestations and complications of COVID-19 Michael Gottlieb, MD a,⁎,BritLong,MDb a Department of Emergency Medicine, Rush University Medical Center, United States of America b Department of Emergency Medicine, Brooke Army Medical Center, United States of America article info abstract Article history: The novel coronavirus disease of 2019 (COVID-19) is associated with significant morbidity and mortality. While Received 9 May 2020 much of the focus has been on the cardiac and pulmonary complications, there are several important dermato- Accepted 3 June 2020 logic components that clinicians must be aware of. Available online xxxx Objective: This brief report summarizes the dermatologic manifestations and complications associated with COVID-19 with an emphasis on Emergency Medicine clinicians. Keywords: COVID-19 Discussion: Dermatologic manifestations of COVID-19 are increasingly recognized within the literature. The pri- fi SARS-CoV-2 mary etiologies include vasculitis versus direct viral involvement. There are several types of skin ndings de- Coronavirus scribed in association with COVID-19. These include maculopapular rashes, urticaria, vesicles, petechiae, Dermatology purpura, chilblains, livedo racemosa, and distal limb ischemia. While most of these dermatologic findings are Skin self-resolving, they can help increase one's suspicion for COVID-19. Emergency medicine Conclusion: It is important to be aware of the dermatologic manifestations and complications of COVID-19. Knowledge of the components is important to help identify potential COVID-19 patients and properly treat complications. © 2020 Elsevier Inc. -
Pp-03-25-New Dots.Qxd 10/23/02 2:41 PM Page 778
pp-03-25-new dots.qxd 10/23/02 2:41 PM Page 778 778 PRAESODYMIUM PRAESODYMIUM [7440–10–0] Symbol Pr; atomic number 59; atomic weight 140.908; a lanthanide–series rare earth element; belongs to the cerium group of rare earths; electron con- figuration [Xe] 4f36s2; partially filled f subshell; valence states +3, +4; most 3+ stable oxidation state +3; electrode potential E°/V (aq) for Pr + 3e¯ ↔ Pr is –2.35 V; atomic radius 1.828 Å; first ionization potential 5.46 eV; one natu- rally–occurring isotope, Pr–141; twenty–nine artificial radioactive isotopes known in the mass range 124, 126–140 and 142–154; the longest–lived isotope Pr–143, t1/2 13.57 day, and the shortest–lived isotope Pr–124, t1/2 1.2 second. History, Occurrence, and Uses Mosander extracted from the mineral lanthana a rare earth fraction, named didymia in 1841. In 1879, Boisbaudran separated a rare earth oxide called samaria (samarium oxide) from the didymia fraction obtained from the mineral samarskite. Soon after that in 1885, Baron Auer von Welsbach iso- lated two other rare earths from didymia. He named them as praseodymia (green twin) and neodymia (new twin) after their source didymia (twin). The name praseodymium finally was assigned to this new element, derived from the two Greek words, prasios meaning green and didymos meaning twin. Praseodymium occurs in nature associated with other rare earths in a rel- atively high abundance. It is more abundant than some common metals such as silver, gold, or antimony. The average concentration of this metal in the earth’s crust is estimated to be 8.2 mg/kg. -
Spore Strips, Crushable S
303-987-8000 or 800-992-6372 [email protected] Regulatory officials and sterilization experts have voiced concerns regarding the appropriateness of using a Biological Indicator (BI) Ampoule interchangeably with spore strips or other approved self-contained Biological Indicators (BIs). They argued spores in a sealed glass ampoule do not have direct contact with the steam, and this lack of direct contact with the sterilant caused the Ampoule to behave differently than other types of BIs. There was no scientific data to support this argument, only the belief that since the spores do not have direct contact with the steam, the Ampoule should not be used in porous load cycles because a “poor quality steam environment” might not be detected by the Ampoule. This argument disregards the fact that the Ampoule BIs are tested for population, Dvalue and Zvalue by the same standardized methods and equipment that are used to test other BIs. The following report will describe various tests and data collected to determine if the Ampoule BI behaves equivalently to spore strips and other self-contained BIs. Background: Biological Indicators (BIs) are used to determine whether a sterilizer has delivered a lethal cycle. Evaluation of resistant, spore-forming microorganisms processed through steam cycles gives the operator a direct measurement of the lethality delivered by the sterilizer during that particular cycle. The organisms used are of known quantity (population) and resistance (Dvalue). The organisms are packaged in such a way as to allow the sterilant access to the spores, and allow for either enumeration or recovery of surviving organisms. -
Absorbine Veterinary Liniment for Horses
Doc# 03.287 Ver. 11 SAFETY DATA SHEET ABSORBINE® VETERINARY LINIMENT SECTION 1 - PRODUCT AND COMPANY IDENTIFICATION 1.1 Trade Name (as labeled): Absorbine® Veterinary Liniment Synonyms: N/A CAS No: Mixture 1.2 Product Use: Soothes sore muscles and stiff joints 1.3 Company Name: W.F. Young Company Address: 302 Benton Dr Company Address Cont: East Longmeadow, MA 01028 Business Phone: ( 413) 526-9999 Website: www.wfyoung.com 1.4 Emergency Telephone Number: (413) 526-9999 Date of Current Revision: January 17, 2017 Date of Last Revision: August 7, 2015 SECTION 2 - HAZARD IDENTIFICATION EMERGENCY OVERVIEW: This product is a green thin liquid with an acetone odor. Health Hazards: May cause skin, eye, and respiratory system irritation. Flammabilit Hazards: This product is a flammable liquid with a flash point over 20°F (-6. 7°C). Reactivit Hazards: None. Environmental Hazards: The environmental effectsof this product have not been investigated, however release may cause long term adverse environmental effects. US DOT Symbols: EU and GHS Symbols: Signal Word: Danger! 2.1 CLASSIFICATION OF SUBSTANCE OR MIXTURE IN ACCORDANCE WITH 29 CFR 1200 (OSHA HCSl AND THE EUROPEAN UNION DIRECTIVES: This product does meet the definition of a hazardous substance or preparation as defined by 29 CFR 1910. 1200 or the European Union Council Directives 67 /548/EEC, 1999/45/EC, 1272/2008/EC and subsequent Directives. EU HAZARD CLASSIFICATIONOF INGREDIENTS PER DIRECTIVE 1272/2008/EC: IndexNumber: EC# 201-939-0 This substance is not classified in the AnnexVI of Directive 67/548/EEC EC# 200-662-2 This substance is classified in the AnnexVI of Directive 67/548/EEC Index# 606-001-00-8 Substances not listed either individually or in group entries must be self classified. -
Simultaneous Determination of Arsenic, Manganese and Selenium in Human Serum by Neutron Activation Analysis
View metadata,Downloaded citation and from similar orbit.dtu.dk papers on:at core.ac.uk Dec 20, 2017 brought to you by CORE provided by Online Research Database In Technology Simultaneous determination of arsenic, manganese and selenium in human serum by neutron activation analysis Damsgaard, E.; Heydorn, Kaj; Larsen, N.A.; Nielsen, B. Publication date: 1973 Document Version Publisher's PDF, also known as Version of record Link back to DTU Orbit Citation (APA): Damsgaard, E., Heydorn, K., Larsen, N. A., & Nielsen, B. (1973). Simultaneous determination of arsenic, manganese and selenium in human serum by neutron activation analysis. (Denmark. Forskningscenter Risoe. Risoe-R; No. 271). General rights Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. • Users may download and print one copy of any publication from the public portal for the purpose of private study or research. • You may not further distribute the material or use it for any profit-making activity or commercial gain • You may freely distribute the URL identifying the publication in the public portal If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. Risø Report No. 271 O Z 8o* Danish Atomic Energy Commission Bh Research Establishment Risø Simultaneous Determination of Arsenic, Manganese and Selenium in Human Serum by Neutron Activation Analysis by E. -
Demae-Can / 2484
Demae-can / 2484 COVERAGE INITIATED ON: 2017.12.25 LAST UPDATE: 2021.06.25 Shared Research Inc. has produced this report by request from the company discussed herein. The aim is to provide an “owner’s manual” to investors. We at Shared Research Inc. make every effort to provide an accurate, objective, neutral analysis. To highlight any biases, we clearly attribute our data and findings. We always present opinions from company management as such. The views are ours where stated. We do not try to convince or influence, only inform. We appreciate your suggestions and feedback. Write to us at [email protected] or find us on Bloomberg. Research Coverage Report by Shared Research Inc. Demae-can / 2484 RCoverage LAST UPDATE: 2021.06.25 Research Coverage Report by Shared Research Inc. | https://sharedresearch.jp INDEX How to read a Shared Research report: This report begins with the Trends and outlook section, which discusses the company’s most recent earnings. First-time readers should start at the later Business section. Executive summary ----------------------------------------------------------------------------------------------------------------------------------- 3 Key financial data ------------------------------------------------------------------------------------------------------------------------------------- 5 Recent updates ---------------------------------------------------------------------------------------------------------------------------------------- 6 Highlights ------------------------------------------------------------------------------------------------------------------------------------------------------------ -
0M Mm EC Vc WM W
APII'I'l 25, 1972 P. w. MCCONNAUGHEY 3,658,719 SMOKE GENE-RATING TUBE Filed Oct. 9, 1969 \\\\\\\\\\~\ NJmyj \\\\\\\\\\\\\\\\\~\\\\\\\\\\\~Y \ R v.a la W. WMVc EC mm 0m (like), 1/17/; // - 1/ 1 .. 3,658,719 United States Patent 0 1C€ Patented Apr. 25, 1972 1 2 a perforated envelope 6 of polyethylene tubing heat 3,658,719 sealed at one end 8 and folded over at the other end 10. SMOKE GENERATING TUBE Paul W. McConnaughey, Wilkinsburg, Pa., assignor to As best seen in FIG. 2, the envelope has a plurality of Mine Safety Appliances Company, Pittsburgh, Pa. perforations 12 made as by cutting slits in the tubing Filed Oct. 9, 1969, Ser. No. 865,039 Wall. The perforations provide only small dimension Int. Cl. B01d; B01f; B01j 13/00 openings so that transfer of the volatile acid portion of US. Cl. 252—-359 A 2 Claims the reagent is substantially by diffusion; that is, there is no signi?cant convection ?ow of gases through the en velope. A great variety of methods of making suitable ABSTRACT OF THE DISCLOSURE 10 perforations are well known, such as, for example, slit ting or puncturing with needles or electrical sparks. Base A solid acid reagent and a solid base reagent are sepa reagent 14 is likewise contained in a breakable ampoule rately contained in a breakable ampoule that is enclosed 16 enclosed in perforated envelope 20. Both envelopes in a perforated envelope, which is in turn contained in are contained in a pliable tube 22 with suitable porous a pliable tube. -
TOBACCO WORLD RETAIL PRICES (Ovor 5,000 Retail PI-ICM)
THE CIGAR AND THE TOBACCO WORLD THE POPULAR JOURNAL TOBACCO OVER 40 YEARS OF TRADE USEFULNESS WORLD The Subscription includes : TOBACCO WORLD RETAIL PRICES (Ovor 5,000 Retail PI-ICM). RETAIL PRICES THE TOBACCO WORLD ANNUAL (Containing a word of Trad* Brand*—with Nam* and Addrau In each cms*). Membership of: TOBACCO WORLD SERVICE JUNE 1935 (With Pott Fnta raplUa In all Trad* difficult!**). The Cigar & Tobacco World HIYWOOO A COMPANY LTD. Dmrr How*, Kin—U 3tr*M, Ontry Una, London, W.C1 trantfc OACM f Baadmur. •trmlnfhtn, Uteanar. ToWfTHM i OffUlfrunt, Phono, LonAon. •Phono I TomaU far M1J Published by THE CIGAR & TOBACCO WORLD HEYWOOD & CO., LTD. DRURY HOUSE, RUSSELL STREET, DRURY LANE, LONDON, W.C.2 Branch Offices: MANCHESTER, BIRMINGHAM, LEICESTER Talagrarm : "Organigram. Phono, London." Phono : Tampla Bar MZJ '' Inar) "TOBACCO WORLD" RETAIL PRICES 1935 Authorised retail prices of Tobaccos, Cigarettes, Fancy Goods, and Tobacconists' Sundries. ABDULLA & Co., Ltd. (\BDULD^ 173 New Bond Street, W.l. Telephone; Bishopsgnte 4815, Authorised Current Retail Prices. Turkish Cigarettes. Price per Box of 100 50 25 20 10 No. 5 14/6 7/4 3/8 — 1/6 No. 5 .. .. Rose Tipped .. 28/9 14/6 7/3 — 3/- No. 11 11/8 5/11 3/- - 1/3 No. II .. .. Gold Tipped .. 13/S 6/9 3/5 - No. 21 10/8 5/5 2/9 — 1/1 Turkish Coronet No. 1 7/6 3/9 1/10J 1/6 9d. No. "X" — 3/- 1/6 — — '.i^Sr*** •* "~)" "Salisbury" — 2/6 — 1/- 6d. Egyptian Cigarettes. No. 14 Special 12/5 6/3 3/2 — — No. -
Nintendo Co., Ltd
Nintendo Co., Ltd. Financial Results Briefing for the Nine-Month Period Ended December 2007 (Briefing Date: 2008/1/25) Supplementary Information [Note] Forecasts announced by Nintendo Co., Ltd. herein are prepared based on management's assumptions with information available at this time and therefore involve known and unknown risks and uncertainties. Please note such risks and uncertainties may cause the actual results to be materially different from the forecasts (earnings forecast, dividend forecast and other forecasts). Nintendo Co., Ltd. Consolidated Statements of Income Transition million yen FY3/2004 FY3/2005 FY3/2006 FY3/2007 FY3/2008 Apr.-Dec.'03 Apr.-Dec.'04 Apr.-Dec.'05 Apr.-Dec.'06 Apr.-Dec.'07 Net sales 439,589 419,373 412,339 712,589 1,316,434 Cost of sales 257,524 232,495 237,322 411,862 761,944 Gross margin 182,064 186,877 175,017 300,727 554,489 (Gross margin ratio) (41.4%) (44.6%) (42.4%) (42.2%) (42.1%) Selling, general, and administrative expenses 79,436 83,771 92,233 133,093 160,453 Operating income 102,627 103,106 82,783 167,633 394,036 (Operating income ratio) (23.3%) (24.6%) (20.1%) (23.5%) (29.9%) Other income 8,837 15,229 64,268 53,793 37,789 (of which foreign exchange gains) ( - ) (4,778) (45,226) (26,069) (143) Other expenses 59,175 2,976 357 714 995 (of which foreign exchange losses) (58,805) ( - ) ( - ) ( - ) ( - ) Income before income taxes and extraordinary items 52,289 115,359 146,694 220,713 430,830 (Income before income taxes and extraordinary items ratio) (11.9%) (27.5%) (35.6%) (31.0%) (32.7%) Extraordinary gains 2,229 1,433 6,888 1,047 3,830 Extraordinary losses 95 1,865 255 27 2,135 Income before income taxes and minority interests 54,423 114,927 153,327 221,734 432,525 Income taxes 19,782 47,260 61,176 89,847 173,679 Minority interests 94 -91 -34 -29 -83 Net income 34,545 67,757 92,185 131,916 258,929 (Net income ratio) (7.9%) (16.2%) (22.4%) (18.5%) (19.7%) - 1 - Nintendo Co., Ltd.